This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2001:166:219-34.

doi: 10.1385/1-59259-114-0:219.

Targeting tumor vasculature using VEGF-toxin conjugates

S Ramakrishnan¹, R Wild, D Nojima

Affiliations

PMID: 11217369
DOI: 10.1385/1-59259-114-0:219

Review

Targeting tumor vasculature using VEGF-toxin conjugates

S Ramakrishnan et al. Methods Mol Biol. 2001.

. 2001:166:219-34.

doi: 10.1385/1-59259-114-0:219.

Authors

S Ramakrishnan¹, R Wild, D Nojima

Affiliation

¹ Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA.

PMID: 11217369
DOI: 10.1385/1-59259-114-0:219

No abstract available

PubMed Disclaimer

Similar articles

Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate.
Olson TA, Mohanraj D, Roy S, Ramakrishnan S. Olson TA, et al. Int J Cancer. 1997 Dec 10;73(6):865-70. doi: 10.1002/(sici)1097-0215(19971210)73:6<865::aid-ijc17>3.0.co;2-3. Int J Cancer. 1997. PMID: 9399667
The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo.
Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, Bicknell R. Zhang HT, et al. Br J Cancer. 2000 Jul;83(1):63-8. doi: 10.1054/bjoc.2000.1279. Br J Cancer. 2000. PMID: 10883669 Free PMC article.
Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Ramakrishnan S, et al. Cancer Res. 1996 Mar 15;56(6):1324-30. Cancer Res. 1996. PMID: 8640821
The regulation of blood vessel growth by vascular endothelial growth factor.
Ferrara N, Heinsohn H, Walder CE, Bunting S, Thomas GR. Ferrara N, et al. Ann N Y Acad Sci. 1995 Mar 27;752:246-56. doi: 10.1111/j.1749-6632.1995.tb17435.x. Ann N Y Acad Sci. 1995. PMID: 7538737 Review. No abstract available.
Vascular endothelial growth factor: basic biology and clinical implications.
Ferrara N, Keyt B. Ferrara N, et al. EXS. 1997;79:209-32. doi: 10.1007/978-3-0348-9006-9_9. EXS. 1997. PMID: 9002234 Review. No abstract available.

See all similar articles

Cited by

Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.
Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC. Niederman TM, et al. Proc Natl Acad Sci U S A. 2002 May 14;99(10):7009-14. doi: 10.1073/pnas.092562399. Epub 2002 May 7. Proc Natl Acad Sci U S A. 2002. PMID: 11997459 Free PMC article.
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA. Chinnasamy D, et al. J Clin Invest. 2010 Nov;120(11):3953-68. doi: 10.1172/JCI43490. Epub 2010 Oct 11. J Clin Invest. 2010. PMID: 20978347 Free PMC article.
The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.
Mohamedali KA, Cao Y, Cheung LH, Hittelman WN, Rosenblum MG. Mohamedali KA, et al. Mol Cancer Ther. 2013 Oct;12(10):2055-66. doi: 10.1158/1535-7163.MCT-13-0165. Epub 2013 Jul 15. Mol Cancer Ther. 2013. PMID: 23858102 Free PMC article.
Targeting of Tumor Neovasculature with GrB/VEGF₁₂₁, a Novel Cytotoxic Fusion Protein.
Mohamedali KA, Rosenblum MG. Mohamedali KA, et al. Biomedicines. 2017 Jul 17;5(3):42. doi: 10.3390/biomedicines5030042. Biomedicines. 2017. PMID: 28714916 Free PMC article. Review.

Publication types

Actions

MeSH terms

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- The Lens - Patent Citations Database